<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475563</url>
  </required_header>
  <id_info>
    <org_study_id>BIOSS</org_study_id>
    <nct_id>NCT03475563</nct_id>
  </id_info>
  <brief_title>BiOSS Study (BiOSS LIM C Stent Registry in Bifurcated Lesions)</brief_title>
  <acronym>BIOSS</acronym>
  <official_title>BiOSS LIM C Stent Registry in Bifurcated Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BIOSS Lim C pharmacoactive Stent has characteristics of design that makes it very
      suitable for the treatment of bifurcational lesions . The objective of the study is providing
      deeper knowledge into the results of this stent in the treatment of bifurcational lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BIOSS Lim C pharmacoactive Stent has characteristics of design that makes it very
      suitable for the treatment of bifurcational lesions . The objective of the study is providing
      deeper knowledge into the results of this stent in the treatment of bifurcational lesions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Successful angioplasty</measure>
    <time_frame>1 day</time_frame>
    <description>After angiography: TIMI (thrombolysis in myocardial infarction ) 3 (both branches). With respect to reference diameter, none of the segments treated with stent has a residual stenosis&gt; 30% or&gt; 50% in those not treated with stent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>30 days</time_frame>
    <description>Cumulative rate of major adverse cardiovascular events (MACE) including cardiac death, myocardial infarction (MI) and repeated revascularization of the target lesion (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of stent struts malposition</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of stent struts malposition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast media volume</measure>
    <time_frame>1 day</time_frame>
    <description>contrast media volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioplasty time</measure>
    <time_frame>1 day</time_frame>
    <description>Angioplasty time</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Patients with coronary artery disease</arm_group_label>
    <description>(coronary artery disease)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary angioplasty with stent implantation</intervention_name>
    <description>Coronary angioplasty with BiOSS LIM C stent implantation</description>
    <arm_group_label>Patients with coronary artery disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic heart disease referred for coronary revascularization will be
        included with susceptible lesion of coronary intervention in bifurcation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years.

          -  Clinical indication of coronary angioplasty in bifurcated lesion.

          -  Bifurcated lesions with both distal branches at least 2 mm in diameter.

          -  The lesion must be located in the main branch, with a severe stenosis by visual
             estimation at some point in the main branch, with or without involvement of the
             lateral branch.

          -  Express acceptance and signature of informed consent.

        Exclusion Criteria:

          -  Express rejection of the patient to participate in the study.

          -  Exclusive involvement of the lateral branch (Medina lesion 001).

          -  Contraindication for antiplatelet treatment.

          -  Lesions due to restenosis.

          -  Lesions in saphenous grafts.

          -  Total chronic occlusions.

          -  Cardiogenic shock.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imanol Otaegui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d`Hebron , Barcelona, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Imanol Otaegui, MD</last_name>
    <phone>+342746155</phone>
    <email>iotaegui@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imanol Otaegui</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Vall d`Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Imanol Otaegui, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Gil RJ, Bil J, Džavík V, Vassilev D, Kern A, Formuszewicz R, Zalewska-Adamiec M, Dobrzycki S. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial. Can J Cardiol. 2015 May;31(5):671-8. doi: 10.1016/j.cjca.2014.12.024. Epub 2014 Dec 24.</citation>
    <PMID>25828372</PMID>
  </results_reference>
  <results_reference>
    <citation>Gil RJ, Bil J, Vassiliev D, Iñigo Garcia LA. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry. J Interv Cardiol. 2015 Feb;28(1):51-60. doi: 10.1111/joic.12180.</citation>
    <PMID>25689548</PMID>
  </results_reference>
  <results_reference>
    <citation>Gil RJ, Bil J, Grundeken MJ, Iñigo Garcia LA, Vassilev D, Kern A, Pawłowski T, Wykrzykowska JJ, Serruys PW. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry. EuroIntervention. 2016 Nov 20;12(10):1246-1254. doi: 10.4244/EIJY15M10_05.</citation>
    <PMID>26465375</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Dedicated bifurcation stent</keyword>
  <keyword>Cobalt-chromium</keyword>
  <keyword>Sirolimus-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

